Conatumumab
- Generic Name
- Conatumumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 896731-82-1
- Unique Ingredient Identifier
- 1P48L61KM0
- Background
Conatumumab has been used in trials studying the treatment of Sarcoma, Lymphoma, Oncology, Colon Cancer, and Rectal Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-09-12
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- TetraLogic Pharmaceuticals
- Target Recruit Count
- 27
- Registration Number
- NCT01940172
- Locations
- 🇺🇸
TetraLogic research site, Fresno, California, United States
🇺🇸TetraLogic Research Site, Nashville, Tennessee, United States
🇺🇸TetraLogic Research Facility, Dallas, Texas, United States
Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2014-02-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 53
- Registration Number
- NCT00630786
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath